Amphastar Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Mar 16, 2020 and accepted by EDGAR at Mar 16, 2020, 16:49 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-10-01 to 2019-12-31 | $83.4m | us-gaap:Revenues |
| Revenue | 12 months2019-01-01 to 2019-12-31 | $322.4m | us-gaap:Revenues |
| Cost of revenue | 12 months2019-01-01 to 2019-12-31 | $190.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-10-01 to 2019-12-31 | $33.4m | us-gaap:GrossProfit |
| Gross profit | 12 months2019-01-01 to 2019-12-31 | $131.9m | us-gaap:GrossProfit |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $68.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$39.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2019-01-01 to 2019-12-31 | $119.0k | us-gaap:InterestExpense |
| Income tax | 12 months2019-01-01 to 2019-12-31 | $13.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$1.0m | us-gaap:NetIncomeLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | $48.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | $0.98 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-10-01 to 2019-12-31 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2019-01-01 to 2019-12-31 | $1.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-10-01 to 2019-12-31 | 46,840,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2019-01-01 to 2019-12-31 | 49,907,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | $41.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $41.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2019-01-01 to 2019-12-31 | $22.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-12-31 | $73.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $255.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $587.0m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $90.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $159.4m | us-gaap:Liabilities |
| Long-term debt | At period end2019-12-31 | $46.3m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2019-12-31 | $381.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001297184-20-000007. Last ingested by Listed: Nov 6, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.